Luminex Corporation (LMNX)
Stock Price Chart
Key Info
| Market Cap | 1.49B |
| Revenue (ttm) | 369.12M |
| Net Income (ttm) | 11.08M |
| Shares Out | 46.36M |
| EPS (ttm) | 0.25 |
| PE Ratio | 128.86 |
| Forward PE | n/a |
| Dividend | $0.36 |
| Dividend Yield | 1.12% |
Stock Quote
| Trading Day | Aug 10, 2020 |
| Last Price | $32.22 |
| Previous Close | $32.06 |
| Change ($) | 0.16 |
| Change (%) | 0.48% |
| Day's Open | 32.74 |
| Day's Range | 32.22 - 33.61 |
| Day's Volume | 721,658 |
| 52-Week Range | 17.35 - 41.69 |
More Stats
| Market Cap | 1.49B |
| Enterprise Value | 1.42B |
| Earnings Date (est) | Nov 9, 2020 |
| Ex-Dividend Date | Jun 17, 2020 |
| Shares Outstanding | 46.36M |
| Float | 39.99M |
| EPS (basic) | 0.23 |
| EPS (diluted) | 0.25 |
| FCF / Share | 0.50 |
| Dividend | $0.36 |
| Dividend Yield | 1.12% |
| Earnings Yield | 0.78% |
| FCF Yield | 1.51% |
| Payout Ratio | 156.50% |
| Shares Short | 5.43M |
| Short Ratio | 7.46 |
| Short % of Float | 15.43% |
| Beta | 0.71 |
| PE Ratio | 128.86 |
| Forward PE | n/a |
| P/FCF Ratio | 66.12 |
| PS Ratio | 4.05 |
| PB Ratio | 3.05 |
| Revenue | 369.12M |
| Operating Income | 17.68M |
| Net Income | 11.08M |
| Free Cash Flow | 22.59M |
| Net Cash | 78.16M |
| Net Cash / Share | 1.69 |
| Gross Margin | 49.81% |
| Operating Margin | 4.79% |
| Profit Margin | 3.00% |
| FCF Margin | 6.12% |
| ROA | 1.77% |
| ROE | 2.33% |
| ROIC | 6.70% |
Analyst Summary
Analyst Consensus: Hold
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 335 | 316 | 307 | 271 | 238 | 227 | 213 | 203 | 184 | 142 |
| Revenue Growth | 5.96% | 3.02% | 13.28% | 13.85% | 4.73% | 6.35% | 5.35% | 9.9% | 30.22% | - |
| Gross Profit | 183 | 195 | 199 | 180 | 169 | 160 | 144 | 143 | 125 | 96.38 |
| Operating Income | -12.08 | 27.85 | 37.15 | 20.99 | 32.06 | 28.14 | 4.77 | 22.72 | 23.84 | 11.25 |
| Net Income | -3.77 | 18.20 | 28.89 | 13.81 | 36.86 | 39.04 | 7.10 | 12.41 | 14.47 | 5.23 |
| Shares Outstanding | 44.15 | 43.73 | 43.17 | 42.58 | 42.09 | 41.56 | 40.80 | 40.93 | 41.26 | 41.03 |
| Earnings Per Share | -0.09 | 0.41 | 0.67 | 0.32 | 0.86 | 0.93 | 0.17 | 0.30 | 0.34 | 0.12 |
| EPS Growth | - | -38.81% | 109.38% | -62.79% | -7.53% | 447.06% | -43.33% | -11.76% | 183.33% | - |
| Dividend Per Share | 0.30 | 0.24 | 0.24 | - | - | - | - | - | - | - |
| Dividend Growth | 25% | 0% | - | - | - | - | - | - | - | - |
| Operating Cash Flow | 13.54 | 50.90 | 57.43 | 49.68 | 57.38 | 51.34 | 26.90 | 24.28 | 38.29 | 24.18 |
| Capital Expenditures | -16.25 | -21.29 | -14.64 | -13.13 | -18.71 | -17.08 | -18.09 | -9.77 | -9.55 | -11.10 |
| Free Cash Flow | -2.71 | 29.61 | 42.80 | 36.55 | 38.68 | 34.27 | 8.81 | 14.52 | 28.74 | 13.07 |
| Cash & Equivalents | 59.17 | 76.44 | 127 | 93.45 | 141 | 91.69 | 72.44 | 56.40 | 102 | 119 |
| Total Debt | 17.18 | - | - | - | - | - | 1.66 | 2.84 | 3.57 | 4.20 |
| Net Cash / Debt | 41.99 | 76.44 | 127 | 93.45 | 141 | 91.69 | 70.78 | 53.56 | 98.29 | 115 |
| Assets | 544 | 525 | 491 | 451 | 403 | 358 | 306 | 297 | 283 | 266 |
| Liabilities | 78.87 | 57.52 | 52.61 | 47.04 | 34.02 | 37.53 | 36.43 | 37.51 | 31.79 | 30.95 |
| Book Value | 465 | 468 | 438 | 404 | 369 | 320 | 270 | 260 | 251 | 235 |
Company Profile
Company Details
| Full Name | Luminex Corporation |
| Country | United States |
| Employees | 1,257 |
| CEO | Nachum Shamir |
Stock Information
| Ticker Symbol | LMNX |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Unique Identifier | NASDAQ: LMNX |
| IPO Date | March 30, 2000 |
Description
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group A strep assays, ARIES bordetella assays, ARIES GBS assay, and ARIES C. difficile assays; and VERIGENE test cartridges, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.